Baker Tilly and MediSpend Expand compliance NOW suite with Launch of stewardship NOW to Transform Life Sciences Compliance
CHICAGO--(BUSINESS WIRE)--Building on its collaboration with MediSpend, leading advisory, tax and assurance firm Baker Tilly announces the expansion of its healthcare compliance platform, compliance NOW, with the launch of stewardshipNOW, a comprehensive compliance solution that streamlines external funding management for life sciences organizations.
Powered by MediSpend, and building off of the success of engagementNOW, stewardship NOW automates the administration of grants, charitable contributions, sponsorships and investigator-initiated research funding. The solution helps life sciences companies align healthcare funding initiatives with corporate values while meeting evolving regulatory requirements.
With configurable workflows, customizable portals and robust compliance oversight, stewardship NOW simplifies funding processes from submission through payment execution and reconciliation.
'stewardship NOW empowers life sciences companies to manage the complexities with external funding in a compliant, ethical and efficient way,' said Darren Jones, Baker Tilly principal, life sciences consulting. 'Our collaboration with MediSpend combines strategic insight with advanced technology, helping organizations reduce administrative burden, mitigate risk and execute their funding strategies with confidence and integrity.'
Life sciences organizations rely on solutions like stewardship NOW to manage programs for continuing medical education, charitable contributions, corporate sponsorships and patient advocacy funding. Baker Tilly supports organizations in developing global philanthropy strategies, implementing robust compliance controls and driving impactful funding initiatives that respect recipient independence and align with corporate values.
'stewardship NOW marks an important next step in our continued collaboration with Baker Tilly, bringing together our built for purpose technology along with their advisory experience to help life sciences organizations more effectively create and run efficient, transparent and compliant funding programs.' said Seth Houston, Chief Commercial Officer at MediSpend. 'We're excited to continue our collaboration with Baker Tilly to support our shared clients as they make impactful contributions to the healthcare industry.'
Baker Tilly and MediSpend together deliver technology-enabled solutions that help life sciences organizations navigate complex global regulations, reduce risk and improve operational efficiency. The firm's complianceNOW suite also includes:
transparency NOW – A user-friendly platform that streamlines data capture, collection and reporting while helping organizations stay ahead of evolving regulations.
engagement NOW – A comprehensive solution for managing engagements and interactions with healthcare professionals.
kol NOW – An on-demand, self-service portal that streamlines the process of evaluating the expertise of key opinion leaders (KOLs) used in consulting engagements.
fmv NOW – Direct, self-service access to fair market value (FMV) hourly rates across key opinion leader (KOL) tiers, serving as the delivery mechanism for fair market value rate analysis.
For more information about Baker Tilly's compliance NOW solutions, visit: bakertilly.com/products/compliancenow
# # #
About Baker Tilly (bakertilly.com)
Baker Tilly is a leading advisory, tax and assurance firm, providing clients with a genuine coast-to-coast and global advantage in major regions of the U.S. and in many of the world's leading financial centers – New York, London, San Francisco, Los Angeles, Chicago and Boston. Baker Tilly Advisory Group, LP and Baker Tilly US, LLP (Baker Tilly) provide professional services through an alternative practice structure in accordance with the AICPA Code of Professional Conduct and applicable laws, regulations and professional standards. Baker Tilly US, LLP is a licensed independent CPA firm that provides attest services to its clients. Baker Tilly Advisory Group, LP and its subsidiary entities provide tax and business advisory services to their clients. Baker Tilly Advisory Group, LP and its subsidiary entities are not licensed CPA firms.
Baker Tilly Advisory Group, LP and Baker Tilly US, LLP, trading as Baker Tilly, are independent members of Baker Tilly International, a worldwide network of independent accounting and business advisory firms in 143 territories, with 43,500 professionals and a combined worldwide revenue of $5.62 billion. Visit bakertilly.com or join the conversation on LinkedIn, Facebook and Instagram.
MediSpend's best-in-class solutions empower life sciences companies to grow their business compliantly through top-rated solutions and client services. MediSpend provides commercial compliance solutions for the largest pharmaceutical, medical device and dental companies as well as emerging biotech companies across the world.
© Baker Tilly Advisory Group, LP
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Former rivals Baker Tilly and Moss Adams just merged as private equity reshapes accounting. Their CEOs explain why they did the deal.
Baker Tilly and Moss Adams merged this week in a deal that marks another shake-up for mid-market consulting firms and emphasizes the role being played by private equity in US accounting. The two firms, which are both in the tier below the Big Four, have a combined annual revenue of over $3 billion. By joining forces, they've catapulted themselves above BDO, Grant Thornton US, and CLA to become the 6th largest accounting firm by revenue in the US. The move brings together 11,500 employees into one firm that will keep the Baker Tilly name and be an independent member firm in the Baker Tilly International network. In a joint interview, the two CEOs of the merged firms told Business Insider that the move is mutually strategic and will help them navigate the challenges facing the mid-market. "We just added a bunch of arrows into our quiver," said Jeff Ferro, CEO of Baker Tilly. The deal also offers an insight into how private equity is reshaping the industry in the US. In 2024, Baker Tilly sold a stake to the private investment groups Hellman & Friedman (H&F) and Valeas, in the second-largest deal in the sector at the time. Baker Tilly is now, thanks to the merger, the largest firm in the industry to be partly owned by private-equity investors. It's a trend that is redefining the culture and business model of traditional accounting firms. Firms have typically paid out profits to equity partners, who also get a vote on how they are run. Private equity offers an influx of capital to help firms evolve their technology and data, but requires firms to divest the control historically promised to partners, shaking up their culture. Ferro told BI that Baker Tilly's strategic plan had been to grow through acquisition, and was a key part of what H&F bought into when they signed the deal. H&F will also make a "meaningful additional strategic investment in the business" as part of this transaction. "Our chances of executing our strategy were good, and now I think they're great," said Ferro. A merger that expands the firms' reach Combining firms also created strategic advances in geographic reach — Moss Adams is West Coast-focused, while Baker Tilly mostly covers the East, central, and has some international clients. The two firms bring specific industry strengths to the table and different tools and service capabilities to offer clients, Ferro said. "I see us being a $6 billion revenue organization in five years," Ferro said, which would mean doubling their current combined revenues. "It's quite a win," agreed Eric Miles, the former CEO of Moss Adams, who will take over from Ferro as CEO of Baker Tilly when Ferro retires at the end of the year. The needs of the mid-market client base are changing, and they require more scale and breadth of services than they used to, he said. At the same time, the firms themselves are seeing increasing demand for true fixed costs like training and development, and AI. Those kinds of pressures require large organizations to scale to be competitive, he said. Neither firm had to do the merger, Miles said, "But we had this strategic lens on it, saying, 'how can we be stronger? What's going to be required to be a leading competitive firm in the future?'" "The partnership with Baker-Tilly helped us meet all those long-term strategic objectives, which helps us not only deal with these forces, but get out in front and lead in the market," Miles said.
Business Insider
11 hours ago
- Business Insider
‘There's Still Time to Invest in Snowflake Stock,' Says Five-Star Analyst
Although Snowflake (SNOW) shares have already climbed over 35% this year, UBS believes that the software stock still has more room to grow. Following Snowflake's annual Summit in San Francisco, UBS upgraded the stock from Neutral to Buy and raised its price target from $210 to $265. Despite being late to the upgrade, analysts led by five-star rated Karl Keirstead said that Snowflake's performance has only started improving in the last few quarters, and that the broader AI-related investment cycle is just beginning. Confident Investing Starts Here: Indeed, UBS noted that Snowflake is one of the companies benefiting from the need for 'AI-ready' data, along with Palantir (PLTR) and Databricks. The analysts also pointed out that more software companies like Salesforce (CRM), ServiceNow (NOW), and SAP (SAP) are moving into the data space, which they see as evidence of the growing demand for data. As a result, UBS believes that Snowflake investors haven't fully priced in this growth potential yet and that there's still time to invest before the full AI boom happens. Separately, Morgan Stanley kept its Equal-weight rating and $200 price target despite Snowflake's strengths in data security, ease of use, and multi-cloud capabilities. While the analysts led by five-star rated Keith Weiss praised the company's role in secure AI integration, they remain cautious about the stock's high valuation, which sits at about 55 times the expected free cash flow for 2026. Nevertheless, it is worth mentioning that Snowflake's expansion into data engineering and AI has significantly increased its market opportunity and might justify its premium valuation. Is SNOW a Good Buy Right Now? Overall, analysts have a Strong Buy consensus rating on SNOW stock based on 34 Buys, six Holds, and zero Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average SNOW price target of $225.03 per share implies 6.4% upside potential.
Yahoo
13 hours ago
- Yahoo
Why ServiceNow (NOW) is a Top Momentum Stock for the Long-Term
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term. For momentum investors, upward or downward trends in a stock's price or earnings outlook take precedent, so they'll want to zero in on the Momentum Style Score. This Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates. ServiceNow's cloud-based solution — the Now Platform — enables enterprises to digitize workflows. The platform is used by more than 85% of the Fortune 500 and nearly 60% of the Global 2000 enterprises. NOW is a Zacks Rank #3 (Hold) stock, with a Momentum Style Score of B and VGM Score of B. Shares are up 0.2% over the past one week and up 4.4% over the past four weeks. NOW has gained 44.7% in the last one-year period as well. Looking at trading volume, an average of 1,186,228.63 shares exchanged hands over the last 20 trading days. Momentum investors also pay close attention to a company's earnings. For NOW, 12 analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.25 to $16.51 per share for 2025. NOW boasts an average earnings surprise of 6.6%. With strong earnings growth, a good Zacks Rank, and top-tier Momentum and VGM Style Scores, investors should think about adding NOW to their portfolios. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ServiceNow, Inc. (NOW) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
